# Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

> **NCT00638963** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6 (actual)

## Conditions studied

- Breast Neoplasm
- Brain Neoplasm
- Second Neoplasm

## Interventions

- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00638963
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10-02
- **Primary completion:** 2010-06-30
- **Final completion:** 2010-06-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Terminated due to poor accrual
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00638963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00638963, "Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00638963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*